EGRX - Eagle Pharma reports commercial availability of Pemfexy

Eagle Pharmaceuticals (NASDAQ:EGRX) announces the commercial availability of its novel product Pemfexy (pemetrexed for injection). A branded alternative to Eli Lilly's Alimta, Eagle’s PEMFEXY is a ready-to-use liquid with a unique J-code approved to treat nonsquamous non-small cell lung cancer and mesothelioma. "Together with our recent launch of vasopressin and now PEMFEXY, these products represent significant opportunities for Eagle,” stated Scott Tarriff, President and CEO. In February 2020, Eagle received final approval from the FDA of its NDA for PEMFEXY, following the settlement of patent litigation with Eli Lilly in December 2019. The agreement provided for a release of all claims by the parties and allows for an initial entry of Pemfexy into the market on February 1, 2022 and a subsequent uncapped entry on April 1, 2022.

For further details see:

Eagle Pharma reports commercial availability of Pemfexy